News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,688 Results
Type
Article (14902)
Company Profile (299)
Press Release (266481)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79835)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50702)
Employer Resources (31)
FDA (5837)
Job Trends (5167)
News (145079)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (82)
Alliances (21761)
ALS (126)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6031)
Artificial intelligence (262)
Autoimmune disease (115)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3138)
Cardiovascular disease (238)
Career advice (147)
Career pathing (7)
CAR-T (221)
CDC (5)
Cell therapy (568)
Cervical cancer (14)
Clinical research (43690)
Collaboration (1157)
Company closure (2)
Compensation (597)
Complete response letters (40)
COVID-19 (1101)
CRISPR (86)
C-suite (559)
Cystic fibrosis (112)
Data (4339)
Denatured (15)
Depression (93)
Diabetes (255)
Diagnostics (1380)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (193)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31649)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51680)
Executive appointments (625)
FDA (7595)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (989)
Gene editing (182)
Generative AI (22)
Gene therapy (492)
GLP-1 (506)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (192)
Immuno-oncology (42)
Indications (66)
Infectious disease (1206)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (250)
Machine learning (24)
Management (7)
Manufacturing (377)
MASH (130)
Medical device (2663)
Medtech (2672)
Mergers & acquisitions (6618)
Metabolic disorders (729)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1958)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (332)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (334)
Peanut (43)
People (26667)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15480)
Phase 2 (20302)
Phase 3 (12823)
Pipeline (3289)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (655)
Real estate (1448)
Recruiting (12)
Regulatory (9905)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (336)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (72)
Last 7 days (350)
Last 30 days (1240)
Last 365 days (17862)
2026 (1777)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18260)
Australia (3111)
California (7096)
Canada (1843)
China (777)
Colorado (248)
Connecticut (252)
Delaware (236)
Europe (39187)
Florida (905)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (36)
Indiana (161)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5601)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1649)
New Mexico (13)
New York (1768)
North Carolina (831)
North Dakota (6)
Northern California (3488)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1282)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2814)
Tennessee (40)
Texas (910)
United States (23402)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
281,688 Results for "ascidian therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease
January 8, 2026
·
3 min read
Press Releases
Ascidian Therapeutics Announces Formation of Scientific Advisory Board
May 6, 2025
·
5 min read
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Press Releases
Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
June 24, 2025
·
11 min read
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
·
2 min read
·
Tyler Patchen
Policy
FDA Clears Ascidian for First-Ever RNA Editing Trial in US
Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.
January 30, 2024
·
2 min read
·
Tyler Patchen
Genetown
Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced that it will share preclinical data that enabled IND clearance for Phase 1/2 testing for its lead RNA exon editing therapy, ACDN-01, in a poster session at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore, MD, May 7-11, 2024.
April 25, 2024
·
3 min read
Business
Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO
Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners.
November 8, 2023
·
3 min read
Genetown
Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies
Ascidian Therapeutics, a biotechnology company aspiring to treat human diseases by rewriting RNA, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for ACDN-01.
January 29, 2024
·
4 min read
Business
Ascidian Therapeutics Launches to Rewrite RNA
ATP, a leader in life sciences venture capital, today announced the launch of Ascidian Therapeutics, a biotechnology company built and developed by ATP and funded with a $50 million Series A financing.
October 12, 2022
·
6 min read
1 of 28,169
Next
